AIM ImmunoTech Terminates ATM Equity Sales Agreement with Maxim

What Happened
AIM ImmunoTech Inc. announced the mutual termination of its Equity Distribution Agreement (an "at-the-market" or ATM program) with Maxim Group LLC. The company gave notice on July 31, 2026, with the termination effective August 15, 2026. Under the Agreement (originally dated April 1, 2025 and amended April 10, 2026), AIM sold 3,200,736 shares for aggregate gross proceeds of about $2.8 million. The company said it will not incur termination penalties and will not offer or sell additional shares under that Agreement or the related prospectus after termination.

Key Details

• Agreement parties: AIM ImmunoTech Inc. and Maxim Group LLC (Sales Agent).
• Dates: Agreement dated April 1, 2025; amended April 10, 2026; notice given July 31, 2026; termination effective August 15, 2026.
• Sales under the ATM: 3,200,736 shares sold for approximately $2.8 million in gross proceeds (from April 1, 2025 to July 31, 2026).
• No termination penalties; the Termination Agreement exhibit will be filed with AIM’s Form 10-Q for the quarter ended June 30, 2026.

Why It Matters
The ATM program was a vehicle for AIM to raise equity incrementally; its termination means AIM can no longer sell shares under that specific program and prospectus. For investors, this affects one known avenue the company had used for capital raising (3.2 million shares raised for ~$2.8M). The filing does not state replacement financing or reasons for termination, so investors should watch future filings for updates on AIM’s capital-raising plans or alternative financing arrangements.